2-(1-tert-butoxycarbonylazetidin-2-yl)acetic acid | 1781968-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 2-(1-tert-butoxycarbonylazetidin-2-yl)acetic acid
• 英文别名: 2-{1-[(Tert-butoxy)carbonyl]azetidin-2-yl}acetic acid；2-[1-[(2-methylpropan-2-yl)oxycarbonyl]azetidin-2-yl]acetic acid
• CAS: 1781968-79-3
• 化学式: C₁₀H₁₇NO₄
• 分子量: 215.249
• InChiKey: TXLPFPLPMZEOQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(1-tert-butoxycarbonylazetidin-2-yl)acetic acid 在 N-甲基吗啉 、 氯甲酸异丁酯 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl 2-(2-amino-2-oxoethyl)azetidine-1-carboxylate
  参考文献：
  名称：

  [EN] KHK INHIBITORS
  [FR] INHIBITEURS DE KHK

  摘要：

  式(I)的化合物，其中变量取代基在此定义。

  公开号：

  WO2022212194A1

文献信息

• [EN] N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'AMINE N-ACYLE CYCLIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011111875A1

  公开（公告）日：2011-09-15

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, -C(O)-, etc.; W2 is C1- alkylene; W3 is a single bond, methylene, -NH-, -CR4=CR5-, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了一种化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，同时减少了传统的副作用风险，并对与精神分裂症以外的认知功能障碍相关的中枢神经系统疾病具有显著效果。提供了式（1）的N-酰基环胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4=CR5-等；环Q是式（a）的一组，其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a、R1b和R1c分别是相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药用可接受盐。
• [EN] (QUINOLINE OR ISOQUINOLINE)SULFONAMIDES OF CYCLIC AMINES AS ANTIPSYCHOTIC DRUGS<br/>[FR] (QUINOLÉINE OU ISOQUINOLÉINE)SULFONAMIDES D'AMINES CYCLIQUES UTILISÉS COMME MÉDICAMENTS ANTIPSYCHOTIQUES
  申请人：INST FARMAKOLOGII POLSKIEJ AKADEMII NAUK

  公开号：WO2016003296A1

  公开（公告）日：2016-01-07

  The invention relates to compounds of general formula (I) wherein: one of A1 and A2 represents a nitrogen atom and the other a carbon atom optionally substituted by halogen; the wave line between the sulfonamido moiety and B/C rings represents a single bond linking the sulfur atom to a non-bridgehead carbon atom, with the proviso that the part of ring C being detached by the dashed broken line is unsubstituted; n represents an integer from 0 to 3; Y represents a nitrogen or carbon atom; Z represents a 5-6 membered aromatic/ heteroaromatic ring optionally fused with a further aromatic or non- aromatic 5-6 membered heterocycle, the condensed ring system being linked via a non-bridgehead carbon atom. The compounds display high affinity for the D2, D3, 5-HT1A, 5-HT2A- 5-HT6 and 5-HT7 receptors and are useful for the treatment of psychotropic diseases or disorders associated with disturbances of the dopaminergic/ serotoninergic systems such as schizophrenia and autism.

  本发明涉及一般式（I）的化合物，其中：A1和A2中的一个表示氮原子，另一个表示可选地被卤素取代的碳原子；磺酰胺基团和B/C环之间的波浪线表示单键将硫原子连接到非桥头碳原子，但C环的部分被虚线分离时未被取代；n表示0到3的整数；Y表示氮或碳原子；Z表示一个5-6成员芳香/杂芳环，可选地与进一步的芳香或非芳香5-6成员杂环融合，所述的融合环系统通过非桥头碳原子连接。这些化合物显示出对D2、D3、5-HT1A、5-HT2A-5-HT6和5-HT7受体的高亲和力，并可用于治疗与多巴胺能/ 5-羟色胺能系统紊乱相关的精神病性疾病或障碍，如精神分裂症和自闭症。
• N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Maruyama Megumi

  公开号：US20120214790A1

  公开（公告）日：2012-08-23

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar 1 and Ar 2 are aryl or heteroaryl; V is nitrogen, or CR 3 ; W 1 is a single bond, —C(O)—, etc.; W 2 is C 1 -alkylene; W 3 is a single bond, methylene, —NH—, —CR 4 ═CR 5 —, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R 1a , R 1b and R 1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C 1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍表现出高效性，并且降低了传统副作用风险，对于除精神分裂症以外的与认知功能障碍相关的中枢神经系统疾病具有显著的效果。公式（1）中的N-酰基环状胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4═CR5-等；环Q是公式（a）的基团，在其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a，R1b和R1c分别相同或不同，是氢，羟基，卤素，氰基，C1-6烷基等；或其药学上可接受的盐。
• Complement Pathway Modulators and Uses Thereof
  申请人：NOVARTIS AG

  公开号：US20150126492A1

  公开（公告）日：2015-05-07

  The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种I式化合物，一种制造该化合物的方法，以及其作为补体替代途径抑制剂的治疗用途，特别是作为抑制因子B的治疗用途，例如治疗与年龄相关的黄斑部病变和糖尿病视网膜病变。本发明还提供了药理活性剂的组合和制药组合物。
• COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
  申请人：Novartis AG

  公开号：EP2864322B1

  公开（公告）日：2016-04-27